Frontotemporal Dementia Clinical Trial
Official title:
A Single-Center, Open Label Study to Assess the Safety and Tolerability of Metformin in Subjects With C9orf72 Amyotrophic Lateral Sclerosis Over 24 Weeks of Treatment
The primary objective is to assess the safety and tolerability of Metformin in subjects with C9orf72 amyotrophic lateral sclerosis administered for 24 weeks. The overall objective is to determine if Metformin is safe in C9orf72 ALS patients and is a potentially viable therapeutic treatment for C9-ALS that reduces repeat-associated non-canonical start codon - in DNA (non-ATG) (RAN) proteins that are produced by the C9orf72 repeat expansion mutation.
The C9orf72 repeat expansion is the most common cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD). Metformin, a well-tolerated diabetes drug, blocks a key pathway for expression of toxic proteins produced from the C9orf72 repeat expansion via repeat associated non-canonical start codon - in RNA (non-AUG) (RAN) translation. In mouse model of C9-ALS/FTD, metformin treatment decreases RAN protein levels and improves disease features. This current study is a small-scale clinical trial to assess the safety and potential efficacy of metformin for the treatment of C9-ALS/FTD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
| Recruiting |
NCT03272230 -
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
|
N/A | |
| Active, not recruiting |
NCT03987295 -
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
|
Phase 2 | |
| Withdrawn |
NCT05497817 -
A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia
|
N/A | |
| Recruiting |
NCT04918251 -
EEG and TMS-based Biomarkers of ALS, MS and FTD
|
||
| Completed |
NCT01890343 -
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
|
Phase 2 | |
| Completed |
NCT01002300 -
Oxytocin and Social Cognition in Frontotemporal Dementia
|
N/A | |
| Completed |
NCT00376051 -
Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia
|
Phase 4 | |
| Terminated |
NCT00159198 -
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
Phase 1 | |
| Active, not recruiting |
NCT04516499 -
Neurofilament Surveillance Project (NSP)
|
||
| Recruiting |
NCT04747431 -
A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)
|
Phase 1/Phase 2 | |
| Completed |
NCT03636204 -
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
|
Phase 1 | |
| Completed |
NCT01937013 -
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia
|
Phase 2 | |
| Active, not recruiting |
NCT05075187 -
Epidemiological Study in FRONtoTemporal Dementia
|
||
| Not yet recruiting |
NCT05004558 -
Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias
|
N/A | |
| Completed |
NCT02999282 -
Rehabilitative Trial for the Rescue of Neurophysiological Parameters in Progranulin Deficient Subjects
|
N/A | |
| Completed |
NCT00594737 -
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
|
Phase 3 | |
| Recruiting |
NCT03225144 -
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
||
| Active, not recruiting |
NCT04993755 -
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
|
Phase 2 | |
| Recruiting |
NCT04114994 -
Longitudinal Cognitive Assessment by BoCA
|